The Live Cell Encapsulation Market Size was valued at USD 0.3 Billion in 2022 and is projected to grow from USD 0.31 Billion in 2023 to USD 0.41 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.6% during the projected timeframe (2023 - 2032). The key market drivers contributing to market growth and expansion are a growing need for cell encapsulation methods for effectiveness in clinical trials and recognition as a viable method for treating neurological illnesses.Â
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The growing need for cell encapsulation methods for effectiveness in clinical trials is driving market growth.
The rising need for cell encapsulation methods for effectiveness in clinical trials drives market CAGR for live cell encapsulation. One of the primary benefits of live cell encapsulation is the controlled dispensing of cells or bioactive compounds. It is especially beneficial in cell-based treatments, in which the objective is to transport therapeutic cells to a precise place in the body while shielding them from the patient's immune system. As a result, the increasing importance of this for medicinal reasons is expected to drive market expansion over the research period. Furthermore, leading players' technical improvements and creative product launches are expected to provide profitable prospects for the market. Increased research programs to prove the clinical effectiveness of the cell encapsulation procedure are likely to drive market expansion. The increasing use in developing therapeutic solutions for key chronic diseases such as diabetes, cancer, and autoimmune disorders will also contribute to market growth throughout the forecast.
Additionally, the increasing frequency of target illnesses increases the need for replacing sick or damaged tissues. Because the demand for tissue grafts exceeds the supply, regenerative medicine is fast increasing to meet the demand. For example, hydrogel encapsulation creates a 3D habitat for cells, allowing normal cells to continue producing tissues comparable to those seen in the body. Furthermore, living encapsulation provides a novel and superior method in the field of tissue engineering for preventing transplanted organ rejection. As a result, the growing use of live cell encapsulation in regenerative medicine is propelling market expansion.
The abrupt emergence of COVID-19 prompted an increase in efforts to conduct research and development aimed at developing medications and vaccines utilizing innovative technologies such as encapsulation. Also, the COVID-19 infection prompted an upsurge in scientific investigations on the virus's long-term or short-term organ damage. Tissue engineering technologies such as live cell encapsulation are utilized to cure the damage. For example, live cell encapsulation is utilized to treat liver injury by increasing the proliferation and viability of cells rate. As a result of the increased use of encapsulation methods in COVID-19-related studies, the pandemic has had a beneficial influence on the market. Increasing public-private financing and expenditures in cell and gene treatments will likely boost the market over the forecast period.
For instance, according to the International Diabetes Federation's September 2021 forecast, diabetes will affect roughly 537 million individuals (20-79 years) in 2021. Diabetes is estimated to affect 643 million people in 2030, rising to 783 million in 2045. As a result, the increasing number of instances presents a big potential for market players to develop revolutionary live cell encapsulated medicine for treating diabetic patients, which is predicted to increase the market growth. Thus, it is anticipated that throughout the projected timeframe, demand for Live Cell Encapsulation will increase due to the rising need for cell encapsulation methods for effectiveness in clinical trials. Thus, driving the Live Cell Encapsulation market revenue.
Based on Manufacturing techniques, the market segments of Live Cell Encapsulation includes simple dripping and electrostatic dripping. The electrostatic dripping segment dominated the market, accounting for 52% of market revenue (USD 0.2 Billion) in 2022. It catalyzes droplet creation and accelerates the typical droplet formation process by applying electrostatic forces to draw the drops of the opening much quicker than ordinary dripping. The continued expansion within this category is ascribed to procedural advantages such as consistent size distribution and cell viability preservation.
Based on Polymer Types, the  Live Cell Encapsulation market segmentation includes Alginate, HEMA-MMA, Chitosan, and PAN-PVC. The alginate category generated the highest market revenue of about 37% (USD 0.1 billion) in 2022. Alginate is the most often utilized polymer for medicinal drug encapsulation due to aspects that include Alginate's excellent flexibility, homogeneous cell morphologies, and great mechanical durability.
The market segmentation of Live Cell Encapsulation, based on Application, includes Drug Delivery and Others. The drug delivery segment dominated the market, accounting for 72% of market revenue (USD 0.2 Billion) in 2022. This segment's rise is driven by the increased usage of encapsulation of cells for administering medications, which has operational benefits that include enhanced effectiveness, fewer side effects, and enhanced patient condition.
Figure 1:  Live Cell Encapsulation Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the research provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Live Cell Encapsulation market area will dominate this market during the projected timeframe due to rising per capita income spending on medical care and the strong use of new technologies. In addition, increased R&D expenditures by healthcare organizations and the government will boost market growth in the North American region.
Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Â Live Cell Encapsulation Market Share by Region 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe region’s Live Cell Encapsulation market accounts for the second-highest market share due to a widely recognized medical system and the rise of chronic illnesses. Further, the German market of Live Cell Encapsulation holds the largest market share, and the UK market of Live Cell Encapsulation is expected to grow and expand significantly in the European region during the projected timeframe.
The Asia-Pacific Live Cell Encapsulation Market is expected to grow quickly during the projected timeframe. This is because of the large number of chronic illness patients and government attempts for healthcare reform. Moreover, China’s market of Live Cell Encapsulation dominates the market share, and the Indian market of Live Cell Encapsulation is expected to expand and grow steadily in the Asia-Pacific region during the projected timeframe.
Live Cell Encapsulation Key Market Players & Competitive Insights
Leading market players invested heavily in research and Development (R&D) to scale up their manufacturing units and develop technologically advanced solutions, which will help the Live Cell Encapsulation market grow worldwide. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their  footprint, with significant market developments including new product portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings. The Live Cell Encapsulation industry must offer cost-effective and sustainable options to survive in a highly fragmented and dynamic market climate.
Manufacturing locally to minimize operational expenses and offer aftermarket services to customers is one of the critical business strategies organizations use in the  Live Cell Encapsulation industry to benefit customers and capture untapped market share and revenue. The Live Cell Encapsulation industry has recently offered significant advantages to the medicine industry. Moreover, more industry participants are utilizing and adopting cutting-edge Technology has grown substantially. Major players in the Live Cell Encapsulation market, including Balchem Corporation, Sernova Corporation, Blacktrace Holdings, Merck, Neurotech Holdings, Living Cell Technologies, MiKroCaps, and Biotime, are attempting to expand market share and demand by investing in R&D operations to produce sustainable and affordable solutions.
BIO INX® focuses on industrializing substances and bio-inks for three-dimensional bioprinting by leveraging decades of research expertise in polymers and biomaterials. They provide links for three types of additive production innovations: deposition-based 3D printers, electronic light processing, and multiphoton lithography. Bio INX released Hydrobio INX 400 in November 2022, a routine device that enables live cell encapsulation in three-dimensional printing using Nanoscribe's two-photon polymer technique. The compound is developed to allow the encapsulation of cells in conjunction with seeding cells to create complicated biomimetic tissues.
PharmaCyte Biotech, Inc. is a biotechnology and pharmaceutical firm. The company uses a live-cell encapsulation technique to encase living cells utilized in developing cancer and diabetes medicines. It is making strides in medical research and discovering innovative cellular-based medicines for cancer and diabetes. They revealed in March 2022 that they successfully finished a 24-month product stability study the US FDA needs to approve its clinical study drug applicant, CypCaps. The relevance of this feature is that CypCaps now has an expiration date of no less than 24 months when kept at -80 degrees Celsius.
Key Companies in the market of Live Cell Encapsulation include
Live Cell Encapsulation Industry Developments
November 2022:Bio INX released Hydrobio INX 400 in November 2022, a routine device that enables live cell encapsulation in three-dimensional printing using Nanoscribe's two-photon polymer technique. The compound is developed to allow the encapsulation of cells in conjunction with seeding cells to create complicated biomimetic tissues.
April 2022:Cell-in-a-Box stated that the leadership team will attend the 15th International Conference on Innovative Techniques for Treating Diabetes in Barcelona from April 27-30, 2022. It serves as a professional conference that was founded in 2008.
March 2022:PharmaCyte Biotech, Inc. revealed in March 2022 that it successfully finished a 24-month product stability study needed by the US FDAÂ to approve its clinical study drug applicant, CypCaps. The relevance of this feature is that CypCaps now has an expiration date of no less than 24 months when kept at -80 degrees Celsius.
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.3 Billion |
| Market Size 2023 | USD 0.31 Billion |
| Market Size 2032 | USD 0.41 Billion |
| Compound Annual Growth Rate (CAGR) | 3.6% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Manufacturing technique, Polymer Type, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Balchem Corporation, Sernova Corporation, Blacktrace Holdings, Merck, Neurotech Holdings, Living Cell Technologies, MiKroCaps, and Biotime Inc. |
| Key Market Opportunities | As the medications enclosed penetrate the blood-brain barrier, live cell encapsulation is now recognized as a viable method for treating neurological illnesses. |
| Key Market Dynamics | A growing need for cell encapsulation methods for effectiveness in clinical trials |
Live Cell Encapsulation Market Highlights:
Frequently Asked Questions (FAQ) :
The  Live Cell Encapsulation market size was valued at USD 0.3 Billion in 2022.
The  market for Live Cell Encapsulation is estimated to grow and expand at a CAGR of 3.6% during the projected timeframe.
North America had the largest share of the  market
The key players in the market are Balchem Corporation, Sernova Corporation, Blacktrace Holding, Merck, Neurotech Holding, Living Cell Technologies, MiKroCaps, and Biotime Inc.
The Electrostatic Dripping category dominated the market in 2022.
The Alginate had the largest share in the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
